Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D PhRMA sues to block the program

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

A confirmation hearing for NCI Director Monica Bertagnolli will take place sometime in October, said Sen. Bernie Sanders (I-VT), chairman of the Senate Health, Education, Labor, and Pensions Committee.

September 15, 2023

Vol.49 No.34

By Matthew Bin Han Ong

Clinical

Can ctDNA be used as an endpoint for cancer drug development?
Friends collaboration to present initial results July 11

As researchers consider using circulating tumor DNA as an endpoint in clinical trials to evaluate drug efficacy, a collaboration led by Friends of Cancer Research is creating the evidentiary roadmap for the use of ctDNA in regulatory decisions.

July 07, 2023

Vol.49 No.27

By Matthew Bin Han Ong

Drugs & Targets

LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

NCI has awarded LoxiGen Inc. a three-year Fast-track Small Business Technology Transfer grant to develop a drug that targets treatment-resistant triple-negative breast cancer.

June 30, 2023

Vol.49 No.26

In Brief

Hong-yu Li awarded $3.19M NCI grant for drug development

Hong-yu Li, a researcher with the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, recently received a five-year, $3.19 million grant from NCI to work toward advancing therapeutic treatments for certain types of cancer.

April 28, 2023

Vol.49 No.17

Conversation with The Cancer Letter Regulatory News

FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials

FDA last week issued a draft guidance that urges sponsors to conduct randomized controlled trials when they seek accelerated approval.

MD Anderson and Xilis collaborate on preclinical research

MD Anderson Cancer Center and Xilis formed a strategic collaboration to use Xilis’ proprietary MicroOrganoSphere technology in support of preclinical research to accelerate the development of novel cancer therapies.

February 17, 2023

Vol.49 No.07

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D

PhRMA sues to block the program

YOU MAY BE INTERESTED IN

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

Can ctDNA be used as an endpoint for cancer drug development?
Friends collaboration to present initial results July 11

LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

Hong-yu Li awarded $3.19M NCI grant for drug development

FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials

MD Anderson and Xilis collaborate on preclinical research

Renew today!

Subscriber content

Login

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D

PhRMA sues to block the program

YOU MAY BE INTERESTED IN

Obstacles cleared for Bertagnolli’s confirmation as NIH directorSenate HELP Committee schedules hearing

Can ctDNA be used as an endpoint for cancer drug development?Friends collaboration to present initial results July 11

LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC

Hong-yu Li awarded $3.19M NCI grant for drug development

FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials

MD Anderson and Xilis collaborate on preclinical research

Login

Obstacles cleared for Bertagnolli’s confirmation as NIH director
Senate HELP Committee schedules hearing

Can ctDNA be used as an endpoint for cancer drug development?
Friends collaboration to present initial results July 11